Purpose We examined whether the novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate, compound 2, might be an effective treatment for malignant pleural mesothelioma (MPM), reflecting its selective membrane transport by the proton-coupled folate transport (PCFT) over the reduced folate carrier (RFC). Methods HeLa sublines expressing exclusively PCFT (R1-11-PCFT4) or RFC (R1-11-RFC6) and H2452 MPM cells were assayed for transport with [ 3 H]compound 2. [ 3 H]Polyglutamate metabolites of compound 2 were measured in R1-11-PCFT4 and H2452 cells. In vitro cell proliferation assays and colony formation assays were performed. Inhibition of glycinamide ribonucleotide formyltransferase (GARFTase) was assayed by nucleoside protection assays and in situ GARFTase assays with [ 14 C]glycine. In vivo efficacy was established with earlyand advanced-stage H2452 xenografts in severe-combined immunodeficient (SCID) mice administered intravenous compound 2.
Introduction
There are an estimated 2,500 new cases of malignant pleural mesothelioma (MPM) each year in the United States, approximately 70-80 % resulting from workplace exposures to asbestos [4, 16] . In general, symptoms of MPM do not appear until 30-50 years after exposures to asbestos and by the time of diagnosis, the disease is quite advanced. For years, chemotherapy for MPM was ineffective, although several chemotherapy drugs have been shown to generate clinical responses and to prolong patient survivals [8] . Antifolates are active agents for MPM, and pemetrexed (Pmx; Alimta) ( Fig. 1) is an FDA-approved agent for this disease [12] . While Pmx chemotherapy of MPM (in combination with agents such as cisplatin and gemcitabine) results in improved pulmonary function as well as quality of life, as with other antifolates, clinical efficacy of Pmx can be compromised by toxicity to normal tissues.
In 2006, a previously unknown membrane transporter, the proton-coupled folate transporter (PCFT), was reported to mediate low pH (e.g., pH 5.5) membrane transport of folates into the duodenum [28] . Analogous to folate substrates, antifolates such as methotrexate (Mtx) and Pmx ( Fig. 1 ) are generally transport substrates for PCFT, and Pmx is among the best PCFT substrates yet described [17, 18, 38] . However, most classical antifolates including Pmx are also transported by both the reduced folate carrier (RFC; the major folate membrane transporter in tissues and tumors) and folate receptor (FR) a. Recent efforts have begun to focus on discovery of novel cytotoxic antifolates with folate transporter selectivity. Hence, the antifolates PT523 and GW1843U89 are both excellent substrates for RFC but are poorly transported by PCFT [34, 38] . ONX0801 (BGC945) is a small molecule antifolate licensed by Onyx Pharmaceuticals which is a potent inhibitor of thymidylate synthase and a high-affinity substrate for FRa but not RFC [10] . More recently, we described cytotoxic 6-substituted pyrrolo [2,3-d] pyrimidine thienoyl antifolates (compounds 1 and 2) ( Fig. 1 ) with specificities for cellular uptake by FRs and PCFT over RFC, that inhibit glycinamide ribonucleotide (GAR) formyltransferase (GARFTase), the first folate-dependent step in de novo purine nucleotide biosynthesis [17-19, 33, 34] . In in vivo efficacy trials with severe-combined immunodeficient (SCID) mice harboring subcutaneous (SC) human (KB, IGROV1, HepG2, and HeLa) tumors, both 1 and 2 were potent inhibitors of tumor cell proliferation [18, 19, 33, 34] .
The notion of selectively targeting tumors with cytotoxic antifolates via their PCFT membrane transport [15, 17, 19, 20] is especially appealing given the low pH microenvironments of many solid tumors which would seem to favor cellular uptake by PCFT [13, 30, 36] . Indeed, conditions that favor transport of (anti)folate substrates by PCFT are distinct from those for RFC, since PCFT has an acidic pH optimum (pH *5-5.5) and shows appreciable transport activity at pH 6.5-6.8, whereas RFC exhibits a neutral pH optimum (pH 7.2-7.4) with very low levels of transport below pH 7.0 [17, 22, 38, 39] . In terms of tissue specificity, RFC is ubiquitously expressed in normal tissues and tumors [17, 22] . PCFT transcripts are low in most normal human tissues, although PCFT is expressed at high levels in the upper gastrointestinal tract and choroid plexus, as well as in liver and kidney [17, 29, 39] . Notably, a prominent low pH transport route [likely representing human PCFT (hPCFT)], was detected in 29 of 32 human solid tumor cell lines [37] . Moreover, we detected significant levels of hPCFT transcripts in 52 of 53 human solid tumor cell lines (12 from the study by Zhao et al. [37] ), seven of which were derived from MPMs [18] . For ten tumor cell lines, hPCFT protein was detected by western blotting and by [ 3 H]MTX transport at pH 5.5 [19] . hPCFT transcripts were independently confirmed in 8 MPM cell lines by Nutt et al. [23] .
The reported clinical efficacy of Pmx toward MPM may in part reflect the expression of PCFT in this tumor. On this basis, we rationalized that novel 6-substituted pyrrolo [2,3-d] pyrimidine antifolates with appreciable PCFT substrate activities and with far greater specificity toward PCFT over RFC than Pmx might offer significant benefits for selective therapeutic targeting tumors including MPM [17-20, 34, 35] . In this report, we directly test this concept for compound 2, the lead analog from this series. Our results provide compelling proof-of-principle of antitumor efficacy of compound 2 toward MPM cells both in vitro and in vivo, reflecting its selective membrane transport by PCFT over RFC and its extensive metabolism to polyglutamates, resulting in potent inhibition of intracellular GARFTase. 
Materials and methods

Materials
benzoyl}-L-glutamic acid] (Alimta) was provided by Eli Lilly and Co. (Indianapolis, IN). Synthesis and properties of the 6-substituted pyrrolo [2,3-d] pyrimidine antifolates, compounds 1 and 2, were previously described [34, 35] . Other chemicals were obtained from commercial sources in the highest available purities.
Cell lines
HeLa R1-11-RFC6 and R1-11-PCFT4 cells were derived from human RFC (hRFC)-and hPCFT-null R1-11 cells by stable transfections with hemagglutinin (HA)-tagged pZeoSV2(?)-RFC and pZeoSV2(?)-PCFT constructs, respectively [40] . These HeLa sublines along with a hRFCand hPCFT-null R1-11 ''mock'' transfectant [transfected with pZeoSV2 (Invitrogen) only; hereafter, designated simply R1-11] and wild-type HeLa cells were gifts from Dr. I. David Goldman (Albert Einstein School of Medicine, Bronx, NY). The H2452 subline is a patient-derived biphasic MPM cell line [24] and was a gift from Dr. Anil Wali (National Cancer Institute).
Wild-type and the R1-11 HeLa sublines were cultured as previously described [18, 40] . Routine passage of H2452 cells was in complete RPMI 1640 with 10 % fetal bovine serum, antibiotics, and 2 mM L-glutamine.
For cell proliferation assays, R1-11-PCFT4 and R1-11-RFC6 HeLa cells, and H2452 MPM cells were cultured in folate-free RPMI 1640 (pH 7.2) containing 25 nM LCV, supplemented with 10 % dialyzed fetal bovine serum, 2 mM L-glutamine, and antibiotics for at least 2 weeks. The use of 25 nM LCV in these experiments is designed to mimic physiologic reduced folate concentrations in serum [2] . Cells were plated in 96-well culture dishes (5,000 cells/ well; 200 ll/well) in the above medium with a range of drug concentrations (depending on the compound, dilutions were in DMSO or water with appropriate vehicle controls); For some of the in vitro growth inhibition studies, inhibitory effects of the antifolate drugs on de novo thymidylate synthase and purine nucleotide biosynthesis were established by co-incubations with thymidine (10 lM) and adenosine (60 lM), respectively [5-7, 34, 35] . For de novo purine nucleotide biosynthesis, additional protection experiments used 5-amino-4-imidazolecarboxamide (AICA) (320 lM) to distinguish potential inhibitory effects at GARFTase from those at AICA ribonucleotide formyltransferase (AICARFTase) [1, 5, 18, 20] .
For colony-forming assays, H2452 cells were treated with a range of concentrations of compound 2 in folate-free RPMI 1640 medium, supplemented with 25 nM LCV, 10 % dialyzed fetal bovine serum, penicillin-streptomycin solution, and L-glutamine (pH 7.2), in the presence of adenosine (60 lM). After 24 h, the cells were washed (39) with Hank's balanced salts solution, trypsinized, and 1,000 cells were plated in a 60-mm dish in the above media without drug or adenosine. Cells were allowed to outgrow for 10-12 days, at which time the dishes were rinsed with Dulbecco's phosphate-buffered saline (DPBS), 5 % trichloroacetic acid (TCA), and borate buffer (10 mM, pH 8.8), followed by 1 % methylene blue (in borate buffer). The dishes were again rinsed (39) with borate buffer, and stained colonies were counted for calculating percent colony formation relative to the no drug controls.
Real-time RT-PCR analysis of hRFC and hPCFT transcripts
RNAs were isolated from human cell lines including H2452 MPM, wild-type HeLa, and R1-11 and R1-11-PCFT4 HeLa cells using TRIZOL reagent (Invitrogen). cDNAs were synthesized using MuLV reverse transcriptase (Applied Biosystems, Carlsbad, CA) with random hexamers, and purified with the QIAquick PCR Purification Kit (Qiagen, Valencia, CA). Quantitative real-time RT-PCR was performed on a Roche LightCycler 1.2 (Roche, Indianapolis, IN) with gene-specific primers (Table 1S , Supplement) and FastStart DNA Master SYBR Green I enzyme reaction mix (Roche). Transcript levels for hPCFT and hRFC genes were normalized to those for glyceraldehyde-3-phosphate dehydrogenase (GAPDH). External standard curves were constructed for each gene of interest using serial dilutions of linearized templates, prepared by amplifications from suitable cDNA templates, subcloning into a TA-cloning vector (PCR-Topo; Invitrogen), and restriction digestions.
Transport assays
Transport assays with the R1-11 sublines were routinely performed in suspension using cells grown in spinner flasks, whereas transport assays with H2452 MPM cells used monolayer cultures in 60 mm dishes. For the former, cells were collected by centrifugation, washed with DPBS, and the cell pellets (*1 9 10 7 cells) were suspended in transport buffer (2 ml) for drug uptake assays in a shaking water bath. pH-dependent uptake of 0.5 lM [
3 H]Mtx, Pmx, or compound 2 was assayed in cell suspensions over 5 min at 37°C in HEPES-buffered saline (20 mM HEPES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , and 5 mM glucose) (HBS) at pH 6.8 or 7.2, or in 4-morphilinopropane sulfonic (MES)-buffered saline (20 mM MES, 140 mM NaCl, 5 mM KCl, 2 mM MgCl 2 , and 5 mM glucose) (MBS) at pH 5.5 [37] . hPCFT transport is optimal at pH 5.5 but still significant at pH 6.8, whereas hRFC transport decreases dramatically below pH 7 and is negligible at pH 5.5 [17, 22, 38, 39] .
For some experiments, hRFC transport was measured in ''anion-free'' buffer (20 mM HEPES, 235 mM sucrose, pH adjusted to *7.2 with MgO) [14] . Regardless of the transport buffer used, at the end of the incubations, transport was quenched with ice-cold DPBS. Cells were washed 3 times with ice-cold DPBS, and cellular proteins were solubilized with 0.5 N NaOH. Levels of drug uptake were expressed as pmol/mg cell protein, calculated from direct measurements of radioactivity and protein contents of the cell homogenates. Proteins were quantified using Folinphenol reagent [21] .
The pH-dependent uptakes of [ 3 H]Mtx, compound 2, and [
3 H]Pmx in H2452 cells were assayed at 37°C in cell monolayers in 60 mm dishes over 5 min at 37°C using HBS and MBS. Processing, quantitation of drug uptake, and analyses of replicate data sets were as described above.
High-performance liquid chromatography (HPLC) analysis of polyglutamyl derivatives of compound 2 R1-11-PCFT4 and H2452 cells were grown in complete folate-free RPMI 1640 medium, supplemented with 25 nM LCV and 10 % dialyzed fetal bovine serum. Cells were washed with DPBS and incubated in complete RPMI 1640 and 25 mM PIPES/25 mM HEPES (pH 6.8) with 1 lM [ 3 H]compound 2 at 37°C in the presence of 60 lM adenosine. After 16 h, the cells were washed (39) with ice-cold DPBS, then scraped mechanically into 5 ml of ice-cold DPBS and centrifuged (1,800 rpm), and the cell pellets flash frozen. The cell pellets were processed and analyzed for compound 2 polyglutamates exactly as previously described [18, 19] , using a Waters 4 lm Nova-Pak C-18 column (3.9 mm 9 150 mm) with a Nova-Pak 4 lm C18 guard column, and a Varian 9012 ternary gradient pump and a 9050 Varian UV/Vis detector. Intracellular levels of radiolabeled compounds are expressed as pmol/ mg protein, based on calculated percentages of the peaks from the HPLC chromatogram and total pmol/mg of cellular [
3 H]compound 2 [18, 19] .
In situ GARFTase enzyme inhibition assay
formyl GAR as an in situ measure of endogenous GARFTase activity in R1-11-PCFT4 and H2452 cells at pH 6.8 was performed using published methods [1, 5] , with some modifications exactly as described by Kugel Desmoulin et al. [18] .
In vivo efficacy study of compound 2 in H2452 xenografts Methods for protocol design, drug treatment, toxicity evaluation, data analysis, and quantification of tumor cell kill have been described [3, [25] [26] [27] and have been used in our previous studies [34] . Briefly, cultured H2452 MPM cells were implanted subcutaneously (*1 9 10 7 cells/ flank) to establish a solid tumor xenograft model in female NCR SCID mice (NIH DCT/DTP Animal Production Program, Frederick, MD). Once established, the tumor was maintained in serial passage for a minimum of 5 passage generations before experimentation to allow the development of a consistent tumor growth pattern and stable tumor volume doubling times (Tds) of 2.1 days (folate-replete diet) or 2.3 days (folate-deficient diet). Study mice were maintained on either a folate-deficient diet (Harlan-Teklad; Product ID: TD.00434) or a folate-replete diet (Purina Mills Inc; Lab Diet 5021) starting 15 days before subcutaneous tumor implant for the early stage disease study and 5 days before tumor implant for more advanced-stage disease tumors. Serum folate levels were measured prior to the start of therapy and after its completion with a Lactobacillus casei bioassay [32] and were found to approximate levels in humans [18, 34, 35] . Individual mouse body weights for each experiment were within 2 g, and all mice weights were over 18 g (advanced stage) or 20 g (early stage) at the start of therapy. The mice were supplied food and water ad libitum and were housed in a fully accredited AAALAC animal facility under the care and direction of full-time licensed and board-certified staff veterinarians and veterinary technicians. The animals were pooled and implanted bilaterally subcutaneously with 30-60 mg tumor fragments using a 12-gauge trocar and again pooled before unselective distribution to the various treatment and control groups. The day of tumor implant was day 0. The treatment schedule was every 4 days with 4 injections (q4 9 4) for all drugs, starting on day 2 for early stage treatment, when the number of cells was small (between 10 7 and 10 8 cells; below the established limit of palpation). For advanced-stage disease, the tumors were allowed to reach [250 mg in size before the start of chemotherapy (day 10) with the same injection schedule. All trials had 5 mice per group. Standard drugs included Gemcitabine [(Lilly) dosed at 150 mg/kg] and Cisplatin [(Teva) dosed at 2.8 mg/kg], diluted in 0.9 % saline, USP. An organic solvent (ethanol), carrier (Tween-80), and sodium bicarbonate (0.5 % v/v) were used to effect solubilization of compound 2 for injection (32 mg/kg). All drugs were administered by intravenous tail vein injection. The animals were weighed daily and their tumors were measured with a caliper two-to-three times weekly. Mice were sacrificed when the cumulative tumor burden reached 1,500 mg (before disease progression impinged on animal heath). Tumor weights were estimated from two-dimensional measurements [i.e., tumor mass (in mg) = (a 9 b
2 )/ 2, where ''a'' and ''b'' are the tumor length and width in millimeter, respectively]. For calculation of end points, both tumors on each mouse were added together, and the total mass per mouse was used. Qualitative and quantitative end points were used to assess antitumor activities including: (1) T/C [expressed as a percent and calculated by dividing the median treated (T) tumor volume by the median control (C) tumor volume multiplied by 100 during the exponential growth phase (approximately 700-1,200 mg). A T/C value greater than 42 % is considered inactive]; (2) T -C (tumor growth delay) [where T is the median time in days required for the treatment group tumors to reach a predetermined size (e.g., 1,000 mg) and C is the median time in days for the control group tumors to reach the same size; tumor-free survivors were excluded from these calculations]; and (3) calculation of tumor cell kill [log 10 cell kill total (gross) = (T -C)/ (3.32)(Td), where (T -C) is the tumor growth delay, as described above, and Td is the tumor volume doubling time in days, estimated from the best fit straight line from a log-linear growth plot of control group tumors in exponential growth (100-800 mg range)].
Statistical analysis
Biological replicates were analyzed for statistical significance using the student's t test and GraphPad Prism v. 4.0 for the cell line experiments and the Wilcoxon nonparametric test and InStat v. 3.0 were used for the in vivo drug efficacy experiments.
Results
Expression of hPCFT in H2452 human mesothelioma cells
We previously reported that appreciable levels of hPCFT and hRFC transcripts were expressed in seven clinically relevant MPM cell lines by real-time RT-PCR, approximating those in other solid tumor cell lines [18] . FRa levels in the MPM sublines were extremely low and approached the limit of detection, well below the pharmacologically relevant level of FRa in IGROV1 ovarian carcinoma cells. Analogous results were reported by Nutt et al. [23] .
We selected the H2452 MPM (biphasic) cell line from our prior study to begin to explore the question of whether the modest level of hPCFT in these cells was sufficient to deliver PCFT-selective cytotoxic antifolates for therapy. For our study, we correlated levels of hPCFT transcripts (Fig. 2a) and [ 3 H]Mtx transport (0.5 lM, 5 min) at pH 5.5 measured at 37°C (Fig. 2b) for H2452 MPM cells, compared to these parameters for wild-type HeLa cells and engineered HeLa cells ectopically expressing hPCFT (R1-11-PCFT4, derived from the hRFC-and hPCFT-null R1-11 HeLa subline) [40] . By this analysis, transport activity at pH 5.5 closely paralleled levels of hPCFT transcripts. While hPCFT protein was detectable in R1-11-PCFT4 on western blots probed with hPCFT antibody, for H2452 cells, endogenous hPCFT protein levels were below the level of reproducible detection (not shown). These results are consistent with the presence of functional hPCFT in H2452 MPM cells. (Fig. 1) . Additional experiments were performed to directly measure hPCFT uptake of [ 3 H]compound 2 (at 0.5 lM) at pH 5.5 and pH 6.8 over 5 min in H2452 MPM cells and the R1-11 HeLa sublines expressing moderate levels of hPCFT (R1-11-PCFT4) or hRFC (R1-11-RFC6), compared to the R1-11 transporter-null HeLa subline. Transport was also measured (Fig. 3a, b, d ). Transport could be blocked by unlabeled compound 1 (Fig. 3d shows effects of 10 lM compound 1 on (Fig. 3a) . At pH 6.8, reduced albeit still significant uptake of [ 3 H]Pmx in R1-11-PCFT4 and -RFC6 was detected over R1-11 cells (p \ 0.05), although for [ 3 H]compound 2, significant net uptake over the R1-11 subline was detected only for R1-11-PCFT4 cells (p \ 0.05) (Fig. 3b) . To confirm the contribution of RFC to the uptake of Pmx and compound 2, we performed cellular uptake experiments with the R1-11 sublines in ''anion-free'' (Hepes-sucrose-Mg 2? ) buffer at pH 7.2 which augments RFC transport due to the lack of competing anions [14] . (Fig. 3c) . Thus, in contrast to Mtx and Pmx, membrane transport of compound 2 is highly selective for hPCFT over hRFC.
Membrane transport of compound
2 in R1-11 and H2452 sublines Our previous reports established PCFT-selective membrane transport for the 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate compound 2 [19, 35]for [ 3 H]Pmx. For R1-11-PCFT4 and H2452 cells, uptakes for both [ 3 H]compound 2 and [ 3 H]Pmx were increased (3-4-fold) at pH 5.5 over those at pH 6.8
Polyglutamylation of compound 2 in HeLa and H2452 MPM sublines
Membrane transport of Mtx and Pmx provides substrates for conversion to polyglutamates [11] . Given the established importance of polyglutamylation to the antifolate pharmacologic activity of these classical antifolates, we measured this metabolism for compound 2 in R1-11-PCFT4 and H2452 cells. For these experiments, cells were 3 H]compound 2 for 16 h at pH 6.8 in the presence of 60 lM adenosine. Radiolabeled drug metabolites were extracted and analyzed by HPLC. Up to five radiolabeled metabolites of compound 2 were detected, likely corresponding to di-to hexaglutamyl forms (PG 2-6 ), along with the unmetabolized drug. Total drug accumulations and the distributions of the individual drug forms are summarized in Table 1 . These results establish that with both H2452 and R1-11-PCFT4 cells, compound 2 is an excellent substrate for polyglutamylation under conditions (pH 6.8) that favor its membrane transport by hPCFT.
Selective antiproliferative activity of the 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor compound 2 toward hPCFT-expressing HeLa and H2452 human malignant mesothelioma cells When cells are grown in culture, the tissue culture media pH decreases to *6.8, sufficient to support appreciable levels of PCFT transport [20, 37] . In R1-11 HeLa sublines expressing moderate levels of hPCFT (R1-11-PCFT4) or hRFC (R1-11-RFC6), compound 2 was selectively inhibitory toward the hPCFT-expressing cells with limited inhibitory activity toward the hRFC-expressing subline (Fig. 4) . Compound 2 was *4-fold more inhibitory than previously reported [18] for the 4-carbon bridge analog, compound 1 (Fig. 1) , toward R1-11-PCFT4 cells (IC 50 s of 28.2 and 99.2 nM, respectively). Significantly, compound 2 was greater than 35-fold more active toward R1-11-PCFT4 cells than toward the R1-11-RFC6 HeLa subline (IC 50 of 989 nM) (Fig. 4) , a striking departure from the nearly identical IC 50 s with Pmx toward these sublines (59.3 and 81.7 nM, respectively) [18] . These results establish the potency and growth inhibitory selectivity of compound 2 toward hPCFT-over hRFC-expressing R1-11 cells, analogous to our previous findings with engineered CHO sublines expressing these transporters [35] . Although the sublines derived from R1-11 HeLa cells all express minute amounts of FRa [18] , these levels appear to be insufficient to be pharmacologically relevant for cytotoxic drug delivery.
We also tested H2452 MPM cells for sensitivity to growth inhibition by compound 2. H2452 cells were sensitive to compound 2, showing an IC 50 value (80 nM), similar to that for Pmx (67.3 nM) (Fig. 5a, b, respectively) . Growth inhibition toward H2452 cells for compound 2 was not impacted by addition of 200 nM folic acid (data not shown), consistent with its FRa-independent drug uptake in this MPM cell line model. In colony-forming assays with H2452 cells, pretreatment with compound 2 for 24 h, followed by plating without drug, showed a concentrationdependent inhibition of colony formation, establishing its cytotoxicity (Fig. 5c) . Colony formation was completely abolished at 5 lM compound 2.
Clearly, for H2452 and R1-11-PCFT4 cells, both of which express modest levels of hPCFT, compound 2 is a potent inhibitor of cell proliferation. In H2452, this manifests as cytotoxicity.
Compound 2 inhibits cellular GARFTase in H2452 mesothelioma cells
We previously found that compound 2 like compound 1 was a potent inhibitor of de novo purine nucleotide biosynthesis in hPCFT-expressing R2/hPCFT4 CHO cells at the step catalyzed by GARFTase, and that inhibition of cell proliferation or colony formation could be ascribed to GARFTase inhibition and depletion of cellular purine nucleotides [35] .
To extend these findings to H2452 human MPM cells, we initially tested the impact of nucleoside additions on the growth inhibitions induced by compound 2 and Pmx. Nucleoside protection results for compound 2 are shown in Fig. 5b , whereas those for Pmx are in Fig. 5a . The inhibitory effects of Pmx were partially reversed by thymidine (10 lM) with a progressive diminution in the extent of protection at higher Pmx concentrations. Neither adenosine (60 lM) nor AICA (320 lM), a precursor of AICA ribonucleotide (AICAR or ZMP) that bypasses the reaction catalyzed by GARFTase [1, 5] , was protective at up to 1,000 nM Pmx. Conversely, the growth inhibitory effects of compound 2 toward H2452 cells were completely reversed by adenosine alone, but not at all by thymidine alone. Further, growth inhibition by compound 2 was reversed by AICA. These results establish that compound 2 targets de novo purine nucleotide biosynthesis, apparently at the level of GARFTase, in H2452 human mesothelioma cells. Analogous results were obtained for R1-11-PCFT4 HeLa cells treated with compound 2 ( Figure 1S , supplement). We directly measured cellular GARFTase activities in R1-11-PCFT4 HeLa and H2452 MPM cells treated with a range of concentrations of inhibitory antifolates (Pmx, compound 2), using an in situ GARFTase activity assay. This sensitive metabolic assay measures incorporation of [
14 C]glycine into [ 14 C]formyl GAR, the product of GARFTase which accumulates in the presence of azaserine [1, 5, [18] [19] [20] . For both R1-11-PCFT4 and H2452 cells, compound 2 and Pmx inhibited intracellular GARFTase (Fig. 6, panels A and B) . Compound 2 was slightly more potent than was Pmx toward cellular GARFTase, with IC 50 s of 25.1 and 44 nM in R1-11-PCFT4 and H2452 cells, respectively, compared with 33.6 and 69.7 nM, respectively, for Pmx. For Pmx, inhibition was incomplete and plateaued at *80 % at the highest drug concentration (500 nM Pmx) for which compound 2 inhibited GARFTase by[95 %. These results establish that the inhibition of cell proliferation by compound 2 in hPCFT-expressing human tumor cells, including H2452 MPM cells, reflects its potent inhibition of GARFTase.
In vivo efficacy studies with H2452 human mesothelioma xenografts and compound 2
We performed in vivo studies in SCID mice bearing subcutaneous (SC) xenografts of H2452 tumor to determine the antitumor efficacies of compound 2 under early stage and advanced-stage (palpable) disease conditions. Mice were maintained on either a standard folate-replete (control) diet or a folate-deficient diet to decrease serum folates (8-10-fold) to a concentration approximating those in humans [18, 34, 35] , then, implanted bilaterally with H2452 tumor fragments.
For early stage disease, beginning 2 days after transplant, mice were administered compound 2 (32 mg/kg/ dose), gemcitabine (150 mg/kg/dose), or cisplatin (2.8 mg/ kg/dose) (drugs were given at their optimal highest nontoxic levels) on a Q4d 9 4 schedule IV. Against H2452 xenografts, compound 2 [0 % T/C, 20 day growth delay (T -C), 2.6 logs of cell kill] produced antitumor efficacy clearly superior to cisplatin (52 % T/C, 4 day growth delay, 0.5 logs of cell kill; p \ 0.05, calculated from the T/C, T -C, and log 10 kill values for individual mice relative to the median values for the untreated controls). While there was increased efficacy of compound 2 compared to gemcitabine (15 % T/C, 11 day growth delay, 1.4 logs of cell kill), this difference was not statistically significant. For the efficacious drugs, mice tolerated the treatment regimens well as there were no drug-related lethalities or adverse symptoms other than a reversible weight loss (nadirs sustained for body weight loss ranged from a median 8 % for 2 and gemcitabine, to a median 14 % for cisplatin). Mice were also administered Pmx (7.2 mg/kg/dose on a Q4d 9 4 schedule IV for a total dose of 28.8 mg/kg). While this resulted in weight loss (median 15.4 %), this was not accompanied by antitumor activity (97 % T/C, no log kill), likely due to elevated serum thymidine in mice [31] .
As expected, matched treatment control groups (with H2452 implanted into mice maintained on a folate-replete diet) did not respond appreciably to compound 2 (78 % T/ C, 3.2 % weight gain, 3 day growth delay, and 0.4 log cell kill), whereas efficacy responses for the other drugs were essentially equivalent to those obtained with the folatedeficient diet (17 % T/C, 12 % weight loss, 13 day growth delay, and 1.9 log cell kill for gemcitabine; 60 % T/C, 5.3 % weight loss, 7 day growth delay, 1.0 log cell kill for cisplatin). Results for the early stage in vivo efficacy experiment are shown in Fig. 7a and are summarized in Table 2S in the Supplement.
The efficacy response generated by compound 2 under early stage conditions was sufficient to warrant a second efficacy study with SCID mice bearing more advancedstage (palpable) H2452 tumors ( Fig. 7b ; Table 3S , Supplement). For advanced-stage disease, therapy began 10 days post-SC transplant of H2452 cells [median tumor burdens were 270-284 mg for mice on the folate-deficient diet and 280-310 mg for mice on the control (folatereplete) diet]. Mice were administered compound 2 (32 mg/kg) or gemcitabine (150 mg/kg) on the same Q4d 9 4 schedule IV used for the early stage study. Antitumor activities for both 2 (7 % T/C, 22 day growth delay, 2.9 log cell kill) and gemcitabine (0 % T/C, 17 day growth delay, 2.2 log cell kill) were substantial. For T/C, the difference between compound 2 and gemcitabine was not statistically significant (p = 0.25, calculated from the individual T/C values for individual mice relative to the median values for the untreated controls); however, the differences in T -C and log 10 kill values approached statistical significance (p = 0.0625).
Matched treatment control (folate-replete) groups for the advanced disease trial did not respond to compound 2. For mice on the folate-deficient diet, both compound 2 and gemcitabine produced similar numbers of partial (PR) and complete regressions (CR) (Table 3S, Supplement). Toxicities (weight loss) for both compound 2 and gemcitabine were completely reversible.
Taken together, the results of the in vivo efficacy trials with early and advanced-stage H2452 MPM tumors demonstrate potent antitumor activity of compound 2.
Discussion
MPM is a devastating disease with limited treatment options. The average survival for patients diagnosed with MPM is around 1-year and the 5-year survival approximates 10 % [8] . In recent years, newer antifolates such as Pmx and raltitrexed have shown promise, reflected in improved pulmonary function and quality of life, but still result in toxic side effects in patients. High levels of as mean values ± standard errors) as percentages of vehicle controls over a series of drug concentrations. For H2452 cells, IC 50 s for GARFTase inhibition were 44 ± 6 and 68.3 ± 0.8 nM for compound 2 and Pmx, respectively; for R1-11-PCFT4 cells, these values were 25.1 ± 11.8 and 33.6 ± 15.2 nM, respectively membrane transport into MPM were suggested to explain the chemotherapy activity of Pmx toward this disease [2] . Other drugs have shown activity (as single agents or combined with cisplatin) toward mesothelioma and include gemcitabine, irinotecan, and vinorelbine [8, 9, 16] . Although drugs targeting epidermal growth factor (Gefitinib), platelet-derived growth factor (Imatinib), vascular endothelial growth factor (thalidomide, bevacizumab), histone deacetylases (SAHA), and the proteasome (bortezomib) have been tested, results have been discouraging [8, 9, 16] . Clearly, there is an urgent need for new and highly selective medications for this disease.
hPCFT is significantly expressed in clinically relevant human MPM cell lines [18, 23] . In this report, we studied the H2452 human malignant mesothelioma subline, a biphasic subtype composed of a mixture of epithelioid and sarcomatoid cells, representing the most aggressive form of this disease [8] . We further document expression of functional hPCFT in H2452 human malignant mesothelioma cells, and explore its potential for tumor targeting with the novel hPCFT-selective antifolate compound 2. Compound 2 is a prototype and leads analog from an expanded series of 6-substituted pyrrolo [2,3-d] pyrimidine thienoyl antifolates [34, 35] . We demonstrated that compound 2 is an excellent transport substrate for hPCFT in H2452 cells. While compound 2 is also a substrate for FRa and -b [35] , its substrate activity for hRFC in either physiologic or anion-free buffers is nominal. Further, H2452 cells, like other MPM cell lines and primary patient specimens, express minimal amounts of FRa [18, 23] .
Following internalization by hPCFT at pH 6.8, compound 2, like other classical antifolates including its 4-carbon bridge analog (compound 1) and Pmx [18, 19] , was extensively metabolized to higher-order polyglutamate conjugates. By analogy with other classical antifolates such as Mtx and Pmx, polyglutamyl drug forms are required for In vivo efficacy study of compound 2 in H2452 xenografts. Female ICR SCID mice were maintained on a folate-deficient diet ad libitum. a For the early stage disease trial, H2452 human MPM tumor fragments were implanted subcutaneously bilaterally in mice, then non-selectively distributed into 5 mice/group. Chemotherapy began 2 days after tumor implantation, with compound 2 (32 mg/kg/ dose), gemcitabine (150 mg/kg/dose), or cisplatin (2.8 mg/kg/dose) given on a Q4d 9 4 schedule when the number of cells was relatively small (10 7 -10 8 cells; below the established limit of palpation). b For the advanced-stage disease trial, H2452 human MPM tumor fragments were implanted subcutaneously bilaterally in mice, then nonselectively distributed into 5 mice/group. Chemotherapy began 10 days after tumor implantation when tumors were measurable (270-310 mg median tumor burden for treatment groups). Compound 2 (32 mg/kg/dose) and gemcitabine (150 mg/kg/dose) were administered as single agent therapy on a Q4d 9 4 schedule. For early and advanced-stage tumors, compound 2 produced potent antitumor efficacies equivalent (gemcitabine) or exceeding (cisplatin) efficacies for the standard agents. All mice tolerated the treatment regimens well, as there were no drug-related lethalities or adverse symptoms other than a reversible weight loss sustained inhibition of tumor cell proliferation [11] . Our present results with H2452 and R1-11-PCFT4 cells strongly imply that the compound 2 polyglutamate forms are potent inhibitors of GARFTase, the first folate-dependent enzyme in the de novo purine nucleotide biosynthetic pathway. Inhibition of GARFTase in vitro by compound 2 results in severe depletion of purine nucleotides (i.e., ATP) [18] .
Of particular importance to the broader significance of this work is our finding that hPCFT at the modest levels found in the clinically relevant H2452 MPM cell line model, and at moderately acidic pH values readily achievable in tumors, can deliver a potent growth inhibitory dose of compound 2 in vitro. Cytotoxicity was confirmed in clonogenic assays in which pre-treatment of H2452 cells with compound 2 followed by outgrowth in the absence of drug significantly inhibited colony formation. IC 50 values for inhibition of H2452 cell proliferation by compound 2 were similar to those for inhibition of intracellular GARFTase at pH 6.8 by an in situ metabolic assay in which [ 14 
C]glycine accumulates as [
14 C]formyl GAR, the GARFTase reaction product. These in vitro results were extended in vivo with H2452 human tumor xenografts, for which compound 2 was highly active toward both early and more advanced-stage disease, as reflected in %T/C, T -C, and gross log 10 kill.
In summary, we document our continued drug discovery endeavors to identify novel tumor-targeted antifolate drugs that are poorly transported by the ubiquitously expressed RFC relative to the other major (anti)folate transport systems. Our promising results in a clinically relevant cell line model of human MPM argue that compound 2 is a prototype of an entirely new class of chemotherapy drug that warrants further study of its in vitro and in vivo drug efficacy in an expanded cohort of human tumors.
